Abstracts tagged "autoimmune diseases"

Abstract Number: L04 • ACR Convergence 2022
Psoriatic Arthritis Disease Subtypes Mediated by CD8 T Cells Are Phenocopied in a Novel Humanized Murine Model of Psoriasis and Arthritis
Maria de la Luz Garcia-Hernandez¹, Javier Rangel-Moreno¹, Ananta Paine², Soumyaroop Bhattacharya³, Jeffrey Fox⁴, Ernest Meyer⁵, Brian Isett⁵, Riyue Bao⁶, Tullia Bruno⁶ and Christopher Ritchlin⁷, ¹University of Rochester, Rochester, NY, ²ORNA Tx, Southborough, MA, ³Department of Pediatrics, University of Rochester Medical Center, Rochester, NY, ⁴CMSR, University of Rochester Medical Center, Rochester, NY, ⁵UPMC Hillman Cancer Center, Pittsburgh, PA, ⁶University of Pittsburgh, Pittsburgh, PA, ⁷University of Rochester Medical Center, Rochester, NY
Background/Purpose: A pivotal clinical characteristic of psoriatic arthritis (PsA) is disease manifestations in several domains (skin, entheses, joints, spine) and multiple domain involvement is prevalent,…
Abstract Number: L10 • ACR Convergence 2022
Efgartigimod Prevents Necrosis and Allows for Muscle Fiber Regeneration in a Humanized Mouse Model of Immune-mediated Necrotizing Myopathy (IMNM)
Sarah Julien¹, Emma Briand¹, Bas van der Woning², Leentje de ceuninck³, Rachid zoubari¹, olivier benveniste⁴, laurent drouot¹ and olivier boyer⁵, ¹INSERM U1234, PAn’THER FOCIS Center of Excellence, Rouen, France, ²argenx, Boston, MA, ³argenx, Ghent, Belgium, ⁴AP-HP, Pitié-Salpêtrière University Hospital, Department of Internal Medicine and Clinical Immunology, Paris, France, ⁵INSERM U1234, PAn’THER FOCIS Center of Excellence; Rouen University Hospital, Department of Immunology and Biotherapy, Rouen, France
Background/Purpose: Immune-mediated necrotizing myopathy (IMNM) is a severe form of myositis characterized by muscle weakness and elevated creatine kinase levels in serum. The most frequent…
Abstract Number: 0123 • ACR Convergence 2022
Increase of Serum Endothelin-1 Levels in Patients with Interstitial Lung Disease Associated with Autoimmune Diseases
Sara Remuzgo-Martinez¹, Belén Atienza-Mateo¹, Veronica Pulito-Cueto¹, Fernanda Genre¹, Víctor M. Mora-Cuesta¹, David Iturbe-Fernández¹, Virgi Portilla¹, María Sebastián Mora-Gil¹, J Gonzalo Ocejo-Vinyals², Oreste Gualillo³, Alfonso Corrales¹, Santos Castañeda⁴, Raquel Lopez Mejias⁵, José M. Cifrián¹ and Miguel Ángel González-Gay⁶, ¹Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Department of Immunology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Hospital Clínico Universitario de Santiago, SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Santiago de Compostela, Spain, ⁴Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁵IDIVAL, Santander, Spain, ⁶Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Interstitial lung disease (ILD) may occur in patients with a rheumatic autoimmune disease (AD), increasing their morbidity and mortality [1]. In this regard, the…
Abstract Number: 0261 • ACR Convergence 2022
Machine Learning and Computational Pathology Can Reveal Synovial Pathotypes in Mice and Humans
Richard Bell¹, Matthew Brendel², Justin Xiang³, AMP RA/SLE Consortium¹, Edward DiCarlo¹, Jennifer Anolik⁴, Laura Donlin¹, Dana Orange⁵, Edward Schwarz⁴, Lionel Ivashkiv¹ and Fei Wang², ¹Hospital for Special Surgery, New York, NY, ²Weil Cornell Medical College, New York, NY, ³Horace Grant High School, New York, NY, ⁴University of Rochester Medical Center, Rochester, NY, ⁵The Rockefeller University, New York, NY
Background/Purpose: Synovial pathotyping is a critical step in understanding the etiology of inflammatory arthritis as different pathotypes have differential response to therapy. Determining these pathotypes…
Abstract Number: 0589 • ACR Convergence 2022
Restoration of NAD+ Levels in Rheumatoid Arthritis with NAD+ Boosters as a Novel Therapeutic Strategy to Resolve Acute Inflammation
Carlos Pérez-Sánchez¹, Adrián Llamas Urbano², Tomás Cerdó², Laura Muñoz-Barrera¹, Ismael Sánchez-Pareja², Luz Marina Sánchez-Mendoza³, Nuria Barbarroja¹, María Carmen Ábalos-Aguilera⁴, Juan Antonio Moreno⁵, María isabel Burón⁶, José Antonio González-Reyes⁵, Pilar Font¹, Jerusalem Calvo-Gutierrez², Marta Rojas-Gimenez¹, Eduardo Collantes¹, Alejandro Escudero-Contreras², José Manuel Villalba-Montoro⁶ and Chary Lopez-Pedrera¹, ¹IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ²IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, Spain, ³Department of Cell Biology, Physiology and Immunology, University of Córdoba, Campus de Excelencia Internacional Agroalimentario, ceiA3, Cordoba, Spain, Córdoba, Spain, ⁴Imibic/ University of Córdoba/ Reina Sofía Hospital, Córdoba, Spain, ⁵Department of Cell Biology, Physiology and Immunology, University of Córdoba, Campus de Excelencia Internacional Agroalimentario, ceiA3, Córdoba, Spain, ⁶Department of Cell Biology, Physiology and Immunology, University of Córdoba, Campus de Excelencia Internacional Agroalimentario, ceiA3, Cordoba, Spain
Background/Purpose: This study aimed to: 1- Evaluate the levels of NAD+ and gene transcripts involved in its metabolism in Rheumatoid Arthritis (RA) patients. 2- Analyse…
Abstract Number: 0705 • ACR Convergence 2022
Severity of SARS-CoV-2 Omicron Breakthrough Infections in Patients with Rheumatic Immune-mediated Inflammatory Diseases and Healthy Controls: Data from a Prospective Cohort Study
Laura Boekel¹, Yaëlle Besten¹, Femke Hooijberg¹, Rosa Wartena¹, Maurice Steenhuis², Erik Vogelzang³, Maureen Leeuw¹, Sadaf Atiqi¹, Sander Tas⁴, Willem Lems⁵, Marieke van Ham², Filip Eftimov³, Eileen Stalman³, Luuk Wieske³, Taco Kuijpers³, Alexandre Voskuyl⁶, Ronald van Vollenhoven⁷, Martijn Gerritsen¹, Charlotte Krieckaert¹, Theo Rispens², Maarten Boers⁸, Michael Nurmohamed⁹ and Gertjan Wolbink¹, ¹Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, ²Sanquin Research, Amsterdam, Netherlands, ³Amsterdam UMC, location AMC, Amsterdam, Netherlands, ⁴Amsterdam Rheumatology and immunology Center, location AMC, Amsterdam, Netherlands, ⁵Amsterdam Rheumatology and immunology Center, location VUMC, Amsterdam, Netherlands, ⁶Amsterdam UMC, Amsterdam, Netherlands, ⁷Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁸Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ⁹Amsterdam University Medical Center, Kortenhoef, Netherlands
Background/Purpose: The Omicron (B.1.1.529) variant of SARS-CoV-2 is associated with substantially lower hospitalization rates compared with previous variants of SARS-CoV-2 (i.e., Wildtype, Alpha [B.1.1.7] and…
Abstract Number: 0760 • ACR Convergence 2022
Prevalence of Autoimmune Conditions in Metastatic Melanoma Patients Starting Checkpoint Inhibitors
Alexandra Ladouceur¹, Marina Amaral De Avila Machado², Marie Hudson¹, Cristiano Moura³ and Sasha Bernatsky³, ¹McGill University, Montréal, QC, Canada, ²Research Institute of McGill University Health Center, Montréal, QC, Canada, ³Research Institute of the McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Since patients with pre-existing autoimmune conditions are commonly excluded from clinical trials with immune checkpoint inhibitors (ICI), we aimed to describe the characteristics of…
Abstract Number: 0828 • ACR Convergence 2022
Impact of Hospitalization on Clinical Outcomes in Patients with Connective Tissue Disease-associated Interstitial Lung Disease
Navneet Kaur¹, Xianhong Xie², Anna Korogodina³, Krystal L. Cleven⁴, Bibi Ayesha⁵ and Anand Kumthekar⁶, ¹Touro University Medical Group, Sacramento, CA, ²Department of Epidemiology & Population Health/Albert Einstein College of Medicine, Bronx, NY, ³Department of Medicine, Montefiore Medical Center-Wakefield/Albert Einstein College of Medicine, Bronx, NY, ⁴Division of Pulmonary Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ⁵Montefiore Medical Center, Tarrytown, NY, ⁶Division of Rheumatology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and mortality in patients with connective tissue disease (CTD). The aim of our study…
Abstract Number: 1111 • ACR Convergence 2022
Sarcoidosis Rates in BCG-Vaccinated and Unvaccinated Young Adults: A Danish Register-Based Study
Matthew Baker¹, Emese Vágó², Suzanne Tamang³, Erzsébet Horváth-Puhó² and Henrik Sørensen², ¹Stanford University, Stanford, CA, ²Aarhus University Hospital, Aarhus, Denmark, ³Stanford Center for Population Health Sciences, Redwood City, CA
Background/Purpose: The inciting factor or antigen exposure that initiates sarcoidosis remains unknown. However, an infectious trigger such as Mycobacterium spp. or Propionibacterium acnes infection may…
Abstract Number: 1274 • ACR Convergence 2022
Improving Pneumococcal Vaccination Rates Among Immunosuppressed Adults in an Academic Rheumatology Clinic Utilizing a Nurse Driven Protocol
Elena Joerns¹, Nagendra Pokala², Dan Wang³, Joan Reisch³, Reuben Arasaratnam³, Bonnie Bermas¹ and Puneet Bajaj³, ¹UT Southwestern, Dallas, TX, ²University of Texas Southwestern Medical Center, Dallas, TX, ³UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Rheumatology patients are at risk for severe pneumococcal infections due to their underlying disease and immunosuppressive therapy. Current Advisory Committee on Immunization Practices guidelines…
Abstract Number: 1523 • ACR Convergence 2022
Anti-RNPC3 Autoantibodies in Mixed Connective Tissue Disease Are Associated with Systemic Sclerosis Skin Involvement
Darya S. Jalaledin¹, Hajar El Kamouni², Alexandra Albert³, Sabrina Hoa⁴, Josiane Bourre-Tessier⁵, Eric Rich⁵, Jean-Richard Goulet⁶, Martial Koenig⁷, Minoru Satoh⁸, Marvin Fritzler⁹, May Choi¹⁰, Yves Troyanov¹¹, Jean-Luc Senécal, MD¹² and Océane Landon-Cardinal⁵, ¹Division of Internal Medicine, Centre Hospitalier de l'Université de Sherbrooke, Saint-Lambert, Canada, ²Division of Rheumatology, Centre Hospitalier de l'Université de Montréal, Laval, Canada, ³Division of Rheumatology, Centre Hospitalier de l'Université Laval, Québec, QC, Canada, ⁴University of Montreal, Montréal, QC, Canada, ⁵Division of Rheumatology, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁶Division of Rheumatology, Centre Hospitalier de l'Université de Montréal, Saint-Lambert, Canada, ⁷Division of Internal Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁸Department of Human, Information and Science, University of Occupational Environmental Health, Kitakyusyu Fukuoka, Japan, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ¹¹Division of Rheumatology, Hôpital du Sacré-Coeur de Montréal, Montréal, QC, Canada, ¹²Division of Rheumatology, Centre Hospitalier de l'Université de Montréal, Montréal, Canada
Background/Purpose: RNA-binding region containing 3 (RNPC3) protein acts as a molecular bridge, promoting U11/U12 RNP complex formation. In previous studies, systemic sclerosis (SSc) patients who…
Abstract Number: 1738 • ACR Convergence 2022
Characterization of T Cell Subsets in the Synovium of Chronic Inflammatory Joint Diseases
Alexandra Khmelevskaya¹, Miranda Houtman², Kristina Buerki³, Chantal Pauli⁴, Sam Edalat³, Mojca Frank-Bertoncelj³, Oliver Distler⁵, Adrian Ciurea⁶, Caroline Ospelt⁷ and Raphael Micheroli⁸, ¹Center of Experimental Rheumatology, University Hospital of Zurich, Zürich, Switzerland, ²University of Zurich, Schlieren, Switzerland, ³Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zürich, Switzerland, ⁴Department of Pathology, University Hospital Zurich, Zürich, Switzerland, ⁵Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁶University Hospital Zurich, Zürich, Switzerland, ⁷Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁸University Hospital Zurich, Department of Rheumatology, Zürich, Switzerland
Background/Purpose: Rheumatoid arthritis (RA), psoriatic arthritis (PsA), peripheral spondyloarthritis (pSpA), and undifferentiated arthritis (UA) are chronic immune-mediated conditions characterized by joint inflammation. The specific role…
Abstract Number: 2030 • ACR Convergence 2022
Designing of a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Nipocalimab, an FcRn Inhibitor, in Adults with Primary Sjögren’s Syndrome
Jonathan Hubbard¹, Kim Campbell¹, Kathy Sivils¹, Robert Hoffman¹, Kim Hung Lo¹, Jocelyn Leu¹, Sophia Liva¹, Qing Zuraw¹, Anne Stevens¹, Leona Ling², Keith Karcher³, Sindhu Ramchandren³, Hong Sun³, Hal Scofield⁴, Daniel Wallace⁵ and Raphaèle Seror⁶, ¹Janssen Research and Development, LLC, Spring House, PA, ²Janssen Research & Development, LLC, Cambridge, MA, ³Janssen Research & Development, LLC, Titusville, NJ, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Cedars-Sinai Medical Center, Los Angeles, CA, ⁶University Hospital Paris-Saclay, Le Kremlin Bicêtre, France
Background/Purpose: Dysregulated humoral immunity is a hallmark of primary Sjögren's Syndrome (pSS). This dysregulation involves aberrant B-lymphocyte activity resulting in abnormally high immunoglobulin G (IgG)…
Abstract Number: 2272 • ACR Convergence 2022
Temporal Trends in COVID-19 Outcomes Among Patients with Systemic Autoimmune Rheumatic Diseases: From the First Wave to Omicron
Yumeko Kawano¹, Naomi Patel², Xiaosong Wang¹, Claire Cook³, Kathleen Vanni¹, Emily Kowalski¹, Emily Banasiak¹, Grace Qian¹, Michael Diiorio¹, Tiffany Hsu¹, Michael Weinblatt⁴, Derrick Todd¹, Zachary Wallace³ and Jeffrey Sparks⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital, Sale Creek, TN, ³Massachusetts General Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Advances in prevention, testing, and treatment of COVID-19 have contributed to less severe outcomes in the general population, but whether outcomes have improved for…
Abstract Number: 0124 • ACR Convergence 2022
Evaluation of Comorbidity Burden and Its Effect on Lung Disease Progression and Mortality in a Cohort of Patients with Interstitial Pneumonia with Autoimmune Features
Elena Joerns¹, Michelle Ghebranious¹, Traci Adams¹ and Una Makris², ¹UT Southwestern, Dallas, TX, ²UT Southwestern Medical Center and Dallas VA, Dallas, TX
Background/Purpose: Interstitial pneumonia with autoimmune features (IPAF) is a subset of interstitial lung disease (ILD) which manifests with interstitial pneumonia and features of autoimmunity, yet…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.